The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green light to the ...
To unlock AI’s full potential, businesses must know when it fits—and when it doesn’t. Tech experts share how to focus AI where it drives clarity and measurable impact.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback